Antidepressants in Bipolar: Safer Than Previously Thought? When New Data Challenges Firm Beliefs
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Even though the 2014 ISBD Task Force warned against antidepressant monotherapy in bipolar I, this new network meta-analysis found no significant switch risk versus placebo. However, the evidence supporting antidepressant monotherapy remains limited and derives mainly from three older trials using amineptine, tranylcypromine, or paroxetine. Noradrenergic antidepressants like venlafaxine, imipramine, and desipramine may be the most switch-prone agents.
Fields of Study & Subjects
Bipolar Disorder and Treatment
Treatment of Major Depression
Schizophrenia research and treatment
Publication details
- Publication date
- 26 March 2026
- Language
- EN